Small Leucine Rich Proteoglycans (decorin, biglycan and lumican) in cancer

Appunni, Sandeep; Anand, Vivek; Khandelwal, Madhuram; Gupta, Nidhi; Rubens, Muni; Sharma, Alpana

doi:10.1016/j.cca.2019.01.003

Cited by 103 publications

(95 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar observation was made by Appunni et al [35,36] for the role of leucine-rich proteoglycans and the bladder cancer. Leucine-rich proteoglycans are not only required in the matrix for structural framework, but they also show to be effective in controlling various physiological functions.…”

Section: Proteins Identifiedsupporting

confidence: 81%

Stress Urinary Incontinence: A Proteomics Overview

Mitulović¹,

Mohr²,

Koch³

2020

Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice

View full text Add to dashboard Cite

Proteomics research offers one strategy to elucidate the etiology of stress urinary incontinence (SUI) by identification of a significant and sufficient number of proteins, which provides the ability to avoid a preselection of candidate proteins for a possible early detection of the SUI. SUI represents both a psychological as well as an economic burden, and prevalence rates are expected to increase in the future, due to increasing of life expectancy. The classical epidemiology of SUI is well understood, with many environmental and lifestyle risk factors identified, including age, obesity, parity, vaginal delivery, and family history. Despite this, much of the etiology of SUI remains unclear, and it is difficult to predict which women are at risk. This chapter shows some results based on proteomic analysis of the urine proteome, which might give the answer to the question on pathways activated in SUI. Besides proteins originating from the blood, urine contains proteins secreted from the inner wall of the bladder and the urethra, and these proteins might explain the processes involved in genesis of SUI.

show abstract

Section: Proteins Identifiedsupporting

confidence: 81%

Stress Urinary Incontinence: A Proteomics Overview

Mitulović¹,

Mohr²,

Koch³

2020

Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice

View full text Add to dashboard Cite

show abstract

“…In addition, decorin suppresses the ATR/Chk1/Wee1 axis, leading to inhibition of the cell cycle in the G2/M phase via phosphorylation of cyclin-dependent kinase 1 [20]. Moreover, decorin is known to decrease the expression of pro-angiogenic factors, vascular endothelial growth factor A, and hypoxia-inducible factor 1-α, resulting in downregulation of the hepatocyte growth factor and epidermal growth factor receptor signaling axes [45]. In fact, the serum decorin level was negatively correlated with the serum des-γ-carboxy prothrombin level, which is a tumor maker for HCC in this study.…”

Section: Discussionmentioning

confidence: 99%

Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma

Kawaguchi

Yoshio

Sakamoto

et al. 2020

JCM

View full text Add to dashboard Cite

The outcome of patients with hepatocellular carcinoma (HCC) is still poor. Decorin is a small leucine-rich proteoglycan, which exerts antiproliferative and antiangiogenic properties in vitro. We aimed to investigate the associations of decorin with physical function and prognosis in patients with HCC. We enrolled 65 patients with HCC treated with transcatheter arterial chemoembolization (median age, 75 years; female/male, 25/40). Serum decorin levels were measured using enzyme-linked immunosorbent assays; patients were classified into the High or Low decorin groups by median levels. Associations of decorin with physical function and prognosis were evaluated by multivariate correlation and Cox regression analyses, respectively. Age and skeletal muscle indices were not significantly different between the High and Low decorin groups. In the High decorin group, the 6-min walking distance was significantly longer than the Low decorin group and was significantly correlated with serum decorin levels (r = 0.2927, p = 0.0353). In multivariate analysis, the High decorin group was independently associated with overall survival (hazard ratio 2.808, 95% confidence interval 1.016–8.018, p = 0.0498). In the High decorin group, overall survival rate was significantly higher than in the Low decorin group (median 732 days vs. 463 days, p = 0.010). In conclusion, decorin may be associated with physical function and prognosis in patients with HCC.

show abstract

“…Meflin is a glycosylphosphatidylinositol‐anchored extracellular protein with leucine‐rich repeats that interacts with BMP7 . It is possible that Meflin has other binding partners, as do the matricellular proteins decorin and lumican, which are structurally similar to Meflin . In fact, Zhang et al (2018) identified Dvl2, a cytosolic component of the Wnt signaling pathway, as a new Meflin‐interacting protein and revealed that Meflin protects Dvl2 from autophagy‐dependent degradation, which contributes to the regenerative capacity of skeletal muscle stem cells …”

Section: Perspective and Questionsmentioning

confidence: 99%

Cancer‐associated fibroblasts that restrain cancer progression: Hypotheses and perspectives

et al. 2020

View full text Add to dashboard Cite

The roles of cancer-associated fibroblasts (CAF) in the progression of various types of cancers are well established. CAF promote cancer progression through pleiotropic mechanisms, including the secretion of soluble factors and extracellular matrix, physical interactions with cancer cells, and the regulation of angiogenesis, immunity and metabolism. Their contribution to therapeutic resistance is also well appreciated. Therefore, CAF have been considered as a therapeutic target in cancer. However, recent studies in autochthonous pancreatic cancer models suggest that specific subset(s) of CAF exhibit cancer-restraining roles, indicating that CAF are functionally and molecularly heterogeneous, which is supported by recent single-cell transcriptome analyses. While cancer-promoting CAF (pCAF) have been extensively studied, the nature and specific marker(s) of cancer-restraining CAF (rCAF) have remained uncharacterized. Interestingly, a recent study provided insight into the nature of rCAF and suggested that they may share molecular properties with pancreatic stellate cells (PSC) and mesenchymal stem/stromal cells (MSC). Complicating this finding is that PSC and MSC have been shown to promote the formation of a tumor-permissive and tumor-promoting environment in xenograft tumor models. However, these cells undergo significant transcriptional and epigenetic changes during ex vivo culture, which confounds the interpretation of experimental results based on the use of cultured cells. In this short review, we describe recent studies and hypotheses on the identity of rCAF and discuss their analogy to fibroblasts that suppress fibrosis in fibrotic diseases. Finally, we discuss how these findings can be exploited to develop novel anticancer therapies in the future. K E Y W O R D Scancer-restraining cancer-associated fibroblasts, fibrosis, Meflin, mesenchymal stem/stromal cells, tumor microenvironment

show abstract

Small Leucine Rich Proteoglycans (decorin, biglycan and lumican) in cancer

Cited by 103 publications

References 65 publications

Stress Urinary Incontinence: A Proteomics Overview

Stress Urinary Incontinence: A Proteomics Overview

Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma

Cancer‐associated fibroblasts that restrain cancer progression: Hypotheses and perspectives

Contact Info

Product

Resources

About